HIMS Stock Garners Retail Buzz After Launching New Multi-Cancer Detection Test
Synopsis
The company unveiled a blood test to detect signals for more than 50 types of cancer.
Hims & Hers Health, Inc. (HIMS) came under the spotlight on Wednesday after the company unveiled a blood test to detect signals for more than 50 types of cancer, often before symptoms appear.
Called the Hims & Hers Multi-Cancer Test by Galleri, the test uses the company’s digital platform with GRAIL’s advanced cancer screening technology. The multi-cancer early detection test identifies shared cancer signals, including those for cancers that currently lack recommended screening methods.
“GRAIL believes making validated MCED tests available as a complement to recommended cancer screenings can help to increase cancer detection before cancers spread, improve outcomes, and enable this breakthrough technology to be available to more people,” said Josh Ofman, President at GRAIL.
HIMS was among the top trending tickers on Stocktwits while the shares edged 1% lower after the opening bell.
Read update to this developing story on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.